David A. Price

6.7k total citations · 2 hit papers
89 papers, 4.1k citations indexed

About

David A. Price is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, David A. Price has authored 89 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Endocrinology, Diabetes and Metabolism, 28 papers in Surgery and 23 papers in Genetics. Recurrent topics in David A. Price's work include Growth Hormone and Insulin-like Growth Factors (41 papers), Diabetes Management and Research (36 papers) and Pancreatic function and diabetes (25 papers). David A. Price is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (41 papers), Diabetes Management and Research (36 papers) and Pancreatic function and diabetes (25 papers). David A. Price collaborates with scholars based in United States, United Kingdom and Germany. David A. Price's co-authors include Michael B. Ranke, Kerstin Albertsson‐Wikland, Patrick Wilton, Roy W. Beck, Peter Clayton, Tonya D. Riddlesworth, William H. Polonsky, Janet B. McGill, Richard M. Bergenstal and Craig Kollman and has published in prestigious journals such as JAMA, Annals of Internal Medicine and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

David A. Price

88 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections

2017 838 citations Roy W. Beck, Tonya D. Riddlesworth et al. profile →
Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections

2017 449 citations Roy W. Beck, Tonya D. Riddlesworth et al. Annals of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Price United States	32	3.4k	1.5k	1.3k	699	498	89	4.1k
Sandro Loche Italy	35	3.0k 0.9×	826 0.5×	547 0.4×	965 1.4×	615 1.2×	160	4.2k
P. Brunetti Italy	37	3.6k 1.1×	1.3k 0.9×	1.9k 1.5×	1.1k 1.6×	107 0.2×	144	4.8k
D. Lang Germany	19	809 0.2×	523 0.3×	827 0.6×	470 0.7×	136 0.3×	54	2.0k
Ross C. Cuneo Australia	32	3.9k 1.1×	696 0.5×	448 0.3×	964 1.4×	753 1.5×	71	5.4k
Assumpta Caixàs Spain	31	783 0.2×	540 0.4×	753 0.6×	381 0.5×	121 0.2×	149	2.8k
Leanne Groban United States	34	691 0.2×	505 0.3×	863 0.7×	612 0.9×	87 0.2×	129	3.4k
Keizo Ohnaka Japan	31	649 0.2×	530 0.3×	378 0.3×	1.3k 1.9×	168 0.3×	123	3.6k
Rose Gubitosi‐Klug United States	28	1.1k 0.3×	598 0.4×	502 0.4×	565 0.8×	65 0.1×	76	2.6k
Aart‐Jan van der Lely Netherlands	29	1.8k 0.5×	189 0.1×	831 0.6×	512 0.7×	116 0.2×	43	3.5k
Karsten Müssig Germany	30	1.0k 0.3×	341 0.2×	599 0.5×	698 1.0×	79 0.2×	202	2.9k

Countries citing papers authored by David A. Price

Since Specialization

Citations

This map shows the geographic impact of David A. Price's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Price with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Price more than expected).

Fields of papers citing papers by David A. Price

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Price. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Price. The network helps show where David A. Price may publish in the future.

Co-authorship network of co-authors of David A. Price

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Price. A scholar is included among the top collaborators of David A. Price based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Price. David A. Price is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poon, Jiat Ling, Eric S. Meadows, David A. Price, et al.. (2021). Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes. Diabetes Technology & Therapeutics. 24(1). 61–66. 13 indexed citations

Davis, Georgia M., Ryan Bailey, Peter Calhoun, David A. Price, & Roy W. Beck. (2021). Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. Diabetes Technology & Therapeutics. 24(5). 324–331. 20 indexed citations

Johnson, Jennal, et al.. (2019). 83-LB: Missed Insulin Bolus Doses Are Associated with Hypoglycemic Fear. Diabetes. 68(Supplement_1). 1 indexed citations

Beck, Roy W., Tonya D. Riddlesworth, Katrina J. Ruedy, et al.. (2017). Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine. 167(6). 365–374. 449 indexed citations breakdown →

Plisson, Fabien, Timothy A. Hill, Huy N. Hoang, et al.. (2016). Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European Journal of Medicinal Chemistry. 127. 703–714. 20 indexed citations

Peyser, Thomas A., et al.. (2015). Hypoglycemic Accuracy and Improved Low Glucose Alerts of the Latest Dexcom G4 Platinum Continuous Glucose Monitoring System. Diabetes Technology & Therapeutics. 17(8). 548–554. 28 indexed citations

Hoang, Huy N., Kun Song, Timothy A. Hill, et al.. (2015). Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. Journal of Medicinal Chemistry. 58(9). 4080–4085. 38 indexed citations

Eng, Heather, Raman Sharma, Thomas S. McDonald, et al.. (2013). Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor. Drug Metabolism and Disposition. 41(8). 1470–1479. 20 indexed citations

Jones, Lyn H. & David A. Price. (2013). Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists. Progress in medicinal chemistry. 52. 45–96. 12 indexed citations

10.

Ranke, Michael B., Anders Lindberg, David A. Price, et al.. (2007). Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature. Hormone Research in Paediatrics. 68(2). 53–62. 93 indexed citations

11.

Geffner, Mitchell E., Michael Lundberg, Maria Kołtowska‐Häggström, et al.. (2004). Changes in Height, Weight, and Body Mass Index in Children with Craniopharyngioma after Three Years of Growth Hormone Therapy: Analysis of KIGS (Pfizer International Growth Database). The Journal of Clinical Endocrinology & Metabolism. 89(11). 5435–5440. 72 indexed citations

12.

Iles, David, H. Rao Gattamaneni, Jennifer E. Thorne, et al.. (2002). Endocrinology and diabetes. Archives of Disease in Childhood. 86(Supplement 1). 8–11. 3 indexed citations

13.

Burren, Christine, Katie A. Woods, Steven J. Rose, et al.. (2001). Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome. Hormone Research in Paediatrics. 55(3). 125–130. 47 indexed citations

14.

Tillmann, Vallo, Matthew S. Gill, Nandu Thalange, et al.. (2000). Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal children. Growth Hormone & IGF Research. 10(1). 28–36. 8 indexed citations

15.

Price, David A., Patrick Wilton, Pernilla Jönsson, et al.. (1998). Efficacy and Safety of Growth Hormone Treatment in Children with Prior Craniopharyngioma: An Analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Hormone Research in Paediatrics. 49(2). 91–97. 65 indexed citations

16.

Thalange, Nandu, et al.. (1996). Infradian rhythms in urinary growth hormone excretion.. The Journal of Clinical Endocrinology & Metabolism. 81(1). 100–106. 18 indexed citations

17.

Price, David A., D I Johnston, P R Betts, John Buckler, & Malcolm Donaldson. (1994). Biosynthetic human growth hormone treatment in the UK: an audit of current practice. Kabi Pharmacia International Growth Study.. Archives of Disease in Childhood. 71(3). 266–271. 11 indexed citations

18.

Clayton, Peter, et al.. (1993). Urinary growth hormone excretion in the assessment off children with disorders of growth. Clinical Endocrinology. 39(2). 201–206. 9 indexed citations

19.

Clayton, Peter, Stephen M. Shalet, & David A. Price. (1988). Growth response to growth hormone therapy following cranial irradiation. European Journal of Pediatrics. 147(6). 593–596. 48 indexed citations

20.

Price, David A. & Dwight J. Ingle. (1957). Androgenic effects of autotransplants of adrenals in the accessory reproductive glands of adult castrated rats. Revue suisse de zoologie. 64. 743–755. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact